How to buy Crinetics Pharmaceuticals stock | $13.14

Crinetics Pharmaceuticals, Inc is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Crinetics Pharmaceuticals employs 68 staff and has a trailing 12-month revenue of around USD$392,000.

How to buy shares in Crinetics Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Crinetics Pharmaceuticals. Find the stock by name or ticker symbol: CRNX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Crinetics Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$13.14, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Crinetics Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Crinetics Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Crinetics Pharmaceuticals share price

Use our graph to track the performance of CRNX stocks over time.

Crinetics Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$13.14
52-week range	USD$10.63 - USD$26.67
50-day moving average	USD$13.3832
200-day moving average	USD$15.0295
Wall St. target price	USD$33.6
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.62

Buy Crinetics Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Crinetics Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Crinetics Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Crinetics Pharmaceuticals price performance over time

Historical closes compared with the close of $13.14 from 2020-12-18

1 week (2021-01-11)	-8.37%
1 month (2020-12-18)	13.14
3 months (2020-10-16)	-22.93%
6 months (2020-07-17)	-9.38%

1 year (2020-01-17)	-44.77%
2 years (2019-01-18)	-42.87%
3 years (2018-01-15)	N/A
5 years (2016-01-15)	N/A

Crinetics Pharmaceuticals financials

Revenue TTM	USD$392,000
Gross profit TTM	USD$-40,313,000
Return on assets TTM	-24.93%
Return on equity TTM	-42.13%
Profit margin	0%
Book value	$5.687
Market capitalisation	USD$452.4 million

TTM: trailing 12 months

Shorting Crinetics Pharmaceuticals shares

There are currently 1.3 million Crinetics Pharmaceuticals shares held short by investors – that's known as Crinetics Pharmaceuticals's "short interest". This figure is 3% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Crinetics Pharmaceuticals shares can be evaluated.

Crinetics Pharmaceuticals's "short interest ratio" (SIR)

Crinetics Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Crinetics Pharmaceuticals shares currently shorted divided by the average quantity of Crinetics Pharmaceuticals shares traded daily (recently around 164434.64467005). Crinetics Pharmaceuticals's SIR currently stands at 7.88. In other words for every 100,000 Crinetics Pharmaceuticals shares traded daily on the market, roughly 7880 shares are currently held short.

However Crinetics Pharmaceuticals's short interest can also be evaluated against the total number of Crinetics Pharmaceuticals shares, or, against the total number of tradable Crinetics Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crinetics Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Crinetics Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0548% of the tradable shares (for every 100,000 tradable Crinetics Pharmaceuticals shares, roughly 55 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Crinetics Pharmaceuticals.

Find out more about how you can short Crinetics Pharmaceuticals stock.

Crinetics Pharmaceuticals share dividends

We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.

Crinetics Pharmaceuticals share price volatility

Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $10.63 up to $26.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 1.2273. This would suggest that Crinetics Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Crinetics Pharmaceuticals overview

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Crinetics Pharmaceuticals is owned by insiders or institutions?

  Currently 4.501% of Crinetics Pharmaceuticals shares are held by insiders and 95.102% by institutions.

• How many people work for Crinetics Pharmaceuticals?

  Latest data suggests 68 work at Crinetics Pharmaceuticals.

• When does the fiscal year end for Crinetics Pharmaceuticals?

  Crinetics Pharmaceuticals's fiscal year ends in December.

• Where is Crinetics Pharmaceuticals based?

  Crinetics Pharmaceuticals's address is: Building No. 2, San Diego, CA, United States, 92121

• What is Crinetics Pharmaceuticals's ISIN number?

  Crinetics Pharmaceuticals's international securities identification number is: US22663K1079

• What is Crinetics Pharmaceuticals's CUSIP number?

  Crinetics Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 22663K107